Headlines about TESARO (NASDAQ:TSRO) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TESARO earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.750624720876 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media stories that may have impacted Accern’s scoring:
- TESARO Inc (TSRO) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tesaro Incorporated of Class Action Lawsuit and Upcoming Deadline – TSRO (finance.yahoo.com)
- INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Tesaro, Inc. of Commencement of a Class Action … – Business Wire (press release) (businesswire.com)
- TSRO LOSS NOTICE: Rosen Law Firm Reminds TESARO, Inc. Investors of Important Deadline in Class Action– TSRO (finance.yahoo.com)
- INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Tesaro, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2018 (finance.yahoo.com)
Shares of TESARO (NASDAQ:TSRO) traded down $1.79 during midday trading on Friday, hitting $69.23. The company had a trading volume of 1,010,784 shares, compared to its average volume of 1,210,000. The company has a market cap of $3,670.00, a P/E ratio of -8.21 and a beta of 1.51. TESARO has a 1-year low of $59.77 and a 1-year high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.
Several research analysts have recently commented on the company. BidaskClub upgraded TESARO from a “strong sell” rating to a “sell” rating in a research report on Tuesday. Robert W. Baird reiterated a “neutral” rating and issued a $125.00 target price on shares of TESARO in a research report on Monday, October 2nd. Piper Jaffray Companies reiterated a “hold” rating and issued a $65.00 target price on shares of TESARO in a research report on Thursday, January 18th. Jefferies Group reiterated a “hold” rating and issued a $124.00 target price on shares of TESARO in a research report on Friday, November 3rd. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $150.00 target price (down previously from $190.00) on shares of TESARO in a research report on Thursday, January 18th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. TESARO has a consensus rating of “Hold” and a consensus target price of $149.97.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the sale, the senior vice president now owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 40.50% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact TESARO (TSRO) Share Price” was reported by BBNS and is the property of of BBNS. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://baseballnewssource.com/markets/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-tesaro-tsro-share-price/1871615.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.